WEDNESDAY, Aug. 28, 2019 -- Nourianz (istradefylline) tablets have been approved as an add-on treatment to levodopa/carbidopa for adults with Parkinson disease experiencing "off" episodes, the U.S. Food and Drug Administration announced yesterday.
The drug is available in 20-mg or 40-mg doses, but the maximum recommended dosage in patients taking CYP3A4 inhibitors and those with moderate hepatic impairment is 20 mg once daily. The safety information for Nourianz states that use of the drug should be avoided in these patient populations.
THURSDAY, Sept. 5, 2019 -- For the first time, scientists have found four spots on your DNA that might determine whether you wield your pen with your left hand.
Of the four gene regions, three are associated with proteins involved in brain development and structure, according to a genetic analysis of about 400,000 people in the United Kingdom, including more than 38,000 left-handers.